Hemolysis Treatments

Find Hemolysis Treatments

Medications for Hemolysis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemolysis.

Found 3 Approved Drugs for Hemolysis

Voydeya

Generic Name
Danicopan

Voydeya

Generic Name
Danicopan
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: March 29, 2024
Classification: Complement Factor D Inhibitor
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.

Enjaymo

Generic Name
Sutimlimab-Jome

Enjaymo

Generic Name
Sutimlimab-Jome
Form: Injection
Method of administration: Intravenous
FDA approval date: February 04, 2022
Classification: Classical Complement Pathway Inhibitor
ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).

Aspart

Brand Names
FiAsp, Garzulys, Merilog, NovoLog, Orenitram, Remodulin, Treprostinil, Tyvaso, Tyvaso DPI, Yutrepia

Aspart

Brand Names
FiAsp, Garzulys, Merilog, NovoLog, Orenitram, Remodulin, Treprostinil, Tyvaso, Tyvaso DPI, Yutrepia
Form: Injection, Inhalant, Tablet, Kit, Capsule
Method of administration: Subcutaneous, Intravenous, Respiratory (inhalation), Oral
FDA approval date: August 27, 2001
Classification: Insulin Analog
FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ).
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances